Telomir says OSU research shows in-vitro anti-cancer activity
Telomir Pharmaceuticals announced preclinical research with The Ohio State University demonstrating in-vitro anti-cancer activity in human and canine osteosarcoma models, supporting a parallel development pathway in canine osteosarcoma as its TNBC program advances toward site initiation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.